Journal of the Neurological Sciences
Volume 215, Issue 1 , Pages 37-44 , 15 November 2003

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

Received 2 December 2002 ,Revised 8 May 2003 ,Accepted 3 June 2003.

References 

  1. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin. Pharmacother. 2001;2(7):1149–1165
  2. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–1276
  3. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al.  Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 2001;57(12 Suppl. 5):S46–S53 [1998, classical article]
  4. Wolinsky JS, Narayana PA, Johnson KP. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult. Scler. 2001;7(1):33–41
  5. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, et al.  Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 1998;92(1–2):113–121
  6. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001;56(6):702–708
  7. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, et al.  Mechanisms of immunomodulation by glatiramer acetate. Neurology. 2000;55(11):1704–1714
  8. Qin Y, Zhang DQ, Prat A, Pouly S, Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J. Neuroimmunol. 2000;108(1–2):201–206
  9. Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler. 2001;7(4):209–219
  10. Dabbert D, Rosner S, Kramer M, Scholl U, Tumani H, Mader M, et al.  Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci. Lett. 2000;289(3):205–208
  11. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 2000;105(7):967–976
  12. Ragheb S, Abramczyk S, Lisak D, Lisak R. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Mult. Scler. 2001;7(1):43–47
  13. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. U. S. A. 2000;97(21):11472–11477
  14. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58(8 Suppl. 4):S3–S9
  15. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology. 2001;57(4):731–733
  16. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, et al.  T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. U. S. A. 2000;97(13):7446–7451
  17. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, et al.  Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Natl. Acad. Sci. U. S. A. 2001;98(6):3398–3403
  18. Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol. Med. 2002;8(7):319–323
  19. Ziemssen T, Kumpfel T, Klinkert WEF, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1 and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain. 2002;125:2381–2391
  20. Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain. 2002;125(Pt 1):75–85
  21. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al.  Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. J. Exp. Med. 1999;189(5):865–870
  22. Makar TK, Wilt S, Dong Z, Fishman P, Mouradian MM, Dhib-Jalbut S. IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system. J. Interferon Cytokine Res. 2002;22(7):783–791
  23. McTigue DM, Horner PJ, Stokes BT, Gage FH. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J. Neurosci. 1998;18(14):5354–5365
  24. Neumann H, Misgeld T, Matsumuro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc. Natl. Acad. Sci. U. S. A. 1998;95(10):5779–5784
  25. Wei R, Jonakait GM. Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGF-beta1) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat microglia. J. Neuroimmunol. 1999;95(1–2):8–18
  26. Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature. 1992;360(6406):753–755
  27. Gravel C, Gotz R, Lorrain A, Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat. Med. 1997;3(7):765–770
  28. Kobayashi NR, Fan DP, Giehl KM, Bedard AM, Wiegand SJ, Tetzlaff W. BDNF and NT-4/5 prevent atrophy of rat rubrospinal neurons after cervical axotomy, stimulate GAP-43 and Talpha1-tubulin mRNA expression, and promote axonal regeneration. J. Neurosci. 1997;17(24):9583–9595
  29. Mitsumoto H, Ikeda K, Holmlund T, Greene T, Cedarbaum JM, Wong V, et al.  The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. 1994;36(2):142–148
  30. Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 1995;15(12):7810–7820
  31. Kim DH, Gutin PH, Noble LJ, Nathan D, Yu JS, Nockels RP. Treatment with genetically engineered fibroblasts producing NGF or BDNF can accelerate recovery from traumatic spinal cord injury in the adult rat. Neuroreport. 1996;7(13):2221–2225
  32. Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 1999;10(18):2987–2997

PII: S0022-510X(03)00177-1

doi: 10.1016/S0022-510X(03)00177-1

Journal of the Neurological Sciences
Volume 215, Issue 1 , Pages 37-44 , 15 November 2003

Article Tools

* Image Usage & Resolution